Mouse anti Human CD68 antibody, clone Ki-M7 recognizes human CD68 an integral membrane glycoprotein of ~110 kDa also known as Macrosialin or Gp110. CD68 is predominantly expressed on the intracellular lysosomes of macrophages/monocytes, including Kupffer cells, microglia, histiocytes and osteoclasts, and is expressed to a lesser extent by dendritic cells and peripheral blood granulocytes. Elevated expression of CD68 has been demonstrated on CD34+ cells in various human malignancies, including Acute Myeloid Leukemia.
In immunohistochemical studies, CD68 can be used to aid in the identification of blastic NK lymphomas, some B cell lymphomas, and to help diagnose disorders relating to macrophage abnormalities, including malignant histocytosis and Gaucher’s disease.
Clone Ki-M7 has also been reported as being suitable for use in immunoprecipitation studies.
- Target Species
- Species Cross-Reactivity
|Target Species||Cross Reactivity|
|African green monkey
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline.
- Preservative Stabilisers
|1%||Bovine Serum Albumin|
- Human lymph node tissue.
- Store at 4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guaranteed until date of expiry. Please see product label.
- Entrez Gene
- GO Terms
integral to membrane
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of CD68 antibody
|Flow Cytometry 1
- 1Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 20ul of the suggested working dilution to label 106 cells in 100ul.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Negative Isotype Controls Available
Useful Reagents Available
Application Based External Images
Product Specific References
Kreipe, H. et al. (1987) Ki-M7 monoclonal antibody specific for myelomonocytic cell lineage and macrophages in human.
J Histochem Cytochem. 35 (10): 1117-26.
References for CD68 antibody
Micklem, K. et al. (1989) A human macrophage-associated antigen (CD68) detected by six different monoclonal antibodies.
Br J Haematol. 73 (1): 6-11.
Karlsson, K.R. et al. (2008) Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3.
Exp Hematol. 36 (9): 1167-75.
Gottfried, E. et al. (2008) Expression of CD68 in non-myeloid cell types.
Scand J Immunol. 67: 453-63.
Sakakibara, S. et al. (2009) Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells.
J Virol. 83: 2140-53.
Bendelja, K. et al. (2010) Decreased Toll-like receptor 8 expression and lower TNF-α synthesis in infants with acute RSV infection.
Respir Res. 11: 143.
Vergo, S. et al. (2011) Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Brain. 134 (Pt 2): 571-84.
Sadovnikova, E. et al. (2002) The CD68 protein as a potential target for leukaemia-reactive CTL.
Leukemia. 16 (10): 2019-26.